Advertisement
RVPH 外匯新聞
Reviva Pharma Announces Positive Data From DDI Study Of CYP3A4 Enzyme Effect On Brilaroxazine
Biopharmaceutical company Reviva Pharmaceuticals Holdings, Inc. (RVPH) announced Thursday positive data from its recently completed clinical drug-drug interaction (DDI) study investigating the potential effect of CYP3A4 enzyme on brilaroxazine in healthy subjects.
RTTNews
|
867天前
